Well, I think that's also part of it, right
And the weight loss data from the retatrutide Phase 2 trial tells one of the most compelling stories in obesity pharmacotherapy
However, heterogeneity in weight loss response, cost, side effects, and need for injections may limit their use in many pediatric patients [23]
For example, the SELECT trial reported that semaglutide reduced the risk of MACE by 20% (Hazard Ratio (HR) 0.80, 95% confidence interval (CI) 0.720.90) in people with obesity but without diabetes, although several secondary outcomes did not reach statistical significance under hierarchical testing procedures
Hakimis goal is to help you lose weight with the lowest effective dose to minimize the potential for side effects, and your monthly rate wont go up as your dose increases